NEOADJUVANT VIDUTOLIMOD (VIDU) AND NIVOLUMAB (NIVO) RESULTS IN MPR AND IMMUNE ACTIVATION IN HIGH-RISK RESECTABLE MELANOMA (MEL): FINAL PHASE II CLINICAL TRIAL RESULTSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-12-083OA
FIRST-IN-HUMAN TRIAL TO EVALUATE SAFETY, PK/PD AND INITIAL CLINICAL ACTIVITY OF NM21-1480, AN AFFINITY-BALANCED PD-L1X4-1BBXHSA TRISPECIFIC ANTIBODY: RESULTS OF PHASE 1 DOSE ESCALATIONJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
THE PRAME OPPORTUNITY - HIGH PEPTIDE COPY NUMBERS, HOMOGENOUS EXPRESSION AND HIGH PREVALENCE TO ADDRESS A BROAD PATIENT POPULATION ACROSS DIFFERENT SOLID CANCERS WITH TCR-BASED THERAPEUTICSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF E-602, A BI-SIALIDASE FUSION PROTEIN, IN ADVANCED CANCER (GLIMMER-01)JOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-073OA
RADIOMIC AND CLINICAL PREDICTION OF OVERALL AND ORGAN-SPECIFIC RESPONSE TO IPILIMUMABNIVOLUMAB IN MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
PIXATIMOD (P) IN COMBINATION WITH NIVOLUMAB (N) plus /- LOW-DOSE CYCLOPHOSPHAMIDE (CY) IN ADVANCED CANCERS: A PHASE IIA BASKET TRIALJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
TUMOR-INTRINSIC P38 SIGNALING AS A THERAPEUTIC TARGET TO OVERCOME NON-T CELL-INFLAMED TUMORS AND IMMUNOTHERAPY RESISTANCEJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
MELANOMA LYMPH NODE METASTASES ARE ASSOCIATED WITH HYPOXIA AND IMMUNOLOGIC DYSFUNCTIONJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
SYNB1891, A BACTERIUM ENGINEERED TO PRODUCE A STING AGONIST, DEMONSTRATES TARGET ENGAGEMENT IN HUMANS FOLLOWING INTRATUMORAL INJECTIONJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-103OA
UPDATED SURVIVAL OF PATIENTS WITH PREVIOUSLY TREATED METASTATIC UVEAL MELANOMA WHO RECEIVED TEBENTAFUSPJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-101OA
ACTIVATING CD73 ON B CELLS AS A TARGET FOR IMMUNOTHERAPY OF COVID-19 AND VIRAL ASSOCIATED CANCERS: CLINICAL ACTIVITY IN HUMAN PAPILLOMA VIRUS POSITIVE (HPV) HEAD AND NECK SQUAMOUS CELL CANCERS (HNSCC)JOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-103OA
SAFETY AND ANTI-TUMOR ACTIVITY OF TCR-ENGINEERED AUTOLOGOUS, PRAME-DIRECTED T CELLS ACROSS MULTIPLE ADVANCED SOLID CANCERS AT LOW DOSES - CLINICAL UPDATE ON THE ACTENGINE® IMA203 TRIALJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-1011OA
ARTACUS: AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIESJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-101OA
A PHASE 1A/B STUDY OF IK-175, AN ORAL AHR INHIBITOR, ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH LOCALLY DVANCED OR METASTATIC SOLID TUMORS AND UROTHELIAL CARCINOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-100OA
PHASE I DOSE ESCALATION OF KD033, A PDL1-IL15 BISPECIFIC MOLECULE, IN METASTATIC AND ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-100OA
FINAL ANALYSIS: PHASE 1B STUDY INVESTIGATING INTRATUMORAL INJECTION OF TOLL-LIKE RECEPTOR 9 AGONIST VIDUTOLIMOD ± PEMBROLIZUMAB IN PATIENTS WITH PD-1 BLOCKADE-REFRACTORY MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-106OA
THE IMPACT OF EDUCATION ON NOVEL CONCEPTS IN ADJUVANT MELANOMA: A CLOSER LOOK AT HIGH RISK STAGE II DISEASEJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-090PREAI
A PHASE 1/1B DOSE-ESCALATION STUDY OF INTRAVENOUSLY ADMINISTERED SB 11285 ALONE AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-090PREAI
A PHASE 1 EVALUATION OF TEBOTELIMAB, A BISPECIFIC PD-1 X LAG-3 DART® MOLECULE, IN COMBINATION WITH MARGETUXIMAB IN PATIENTS WITH ADVANCED HER2+NEOPLASMSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-099PREAI
A PHASE II TRIAL OF NIVOLUMAB PLUS AXITINIB IN PATIENTS WITH ANTI-PD1 REFRACTORY ADVANCED MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-092PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向